Ariad Pharmaceuticals Inc., of Cambridge, Mass., reported net product revenues from sales of leukemia drug Iclusig (ponatinib) were $33.3 million for the fourth quarter of 2015, an increase of 56 percent from the fourth quarter of 2014. For the year, revenues were $112.5 million, an increase of 102 percent over 2014 product revenues.